A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)

National Allergies, Immunotherapy and RhinoConjunctivitis Survey in America

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01535118

Acronym

AIRS

Enrollment

2765

Registered

2012-02-17

Start date

2012-01-31

Completion date

2012-05-31

Last updated

2017-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinoconjunctivitis

Keywords

Allergies, Immunotherapy

Brief summary

This study will gather information on allergic rhinoconjunctivitis from surveys completed by adults and children.

Interventions

None listed

Study design

Observational model

ECOLOGIC_OR_COMMUNITY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

5 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Diagnosed with hay fever, rhinitis or nasal and/or eye allergies and display symptoms of sneezing, itching, watery eyes, nasal congestion, or other nasal or eye allergy symptoms over the past 12 months OR take any medication for their hay fever, rhinitis, nasal or eye allergies * 5 years of age or older * Have a telephone

Exclusion criteria

* If less than 18 years old and there is no adult available that is knowledgeable about the participant's health

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants Who Experienced Daily Symptoms Due to Allergic Rhinoconjunctivitis (ARC)	Within 12 months prior to survey	Participants were asked about the frequency and severity of ARC symptoms when allergies were at their worst. The percentages of participants who experienced different symptoms of ARC on a daily basis when allergies were at their worst were calculated.
Percentage of Participants Who Experienced Work or School Absence Due to ARC in the Past 12 Months	Within 12 months prior to survey	Participants were asked about the impact of ARC on loss of work and school time. The percentage of participants who experienced work or school absence due to ARC in the prior 12 months was calculated.
Percentage of Participants Who Used Medication to Treat ARC in the Past 12 Months	Within 12 months prior to survey	Participants were asked about prescription and over-the-counter medication use for ARC. The percentages of participants who used prescription and/or over-the-counter medication to treat ARC in the past 12 months were calculated.
Percentage of Participants Who Received Immunotherapy to Treat ARC	Within 12 months prior to survey	Participants who had ever received immunotherapy for ARC were asked about the type of immunotherapy - subcutaneous or sublingual - received. The percentage of participants who received immunotherapy to treat ARC was calculated.
Percentage of Participants Who Received Allergy Shots and Required Supplemental Prescription Allergy Medication	Within 12 months prior to survey	Participants who received subcutaneous immunotherapy (allergy shots) were asked about prescription and over-the-counter medication use. The percentage of participants who received allergy shots to treat ARC, had not taken over-the-counter allergy medication and required supplemental prescription allergy medication for ARC was calculated.

Secondary

Measure	Time frame	Description
Percentage of Participants Who Received Allergy Shots and Had a Co-morbid Condition of Asthma	Within 12 months prior to survey	Participants were asked about co-morbid health conditions. The percentage of participants who had received allergy shots to treat ARC and had asthma was calculated.

Participant flow

Recruitment details

A national probablility sample of 2765 adults & children (age 5+) who had ever been diagnosed with hay fever, allergic rhinitis, rhinoconjunctivitis, nasal allergies or eye allergies & had nasal allergy symptoms in the past 12 months or had taken prescription medicine for allergies were interviewed by telephone about their condition & treatment.

Participants by arm

Arm	Count
Adults and Children With ARC Adults and children with ARC who complete the survey	2,765
Total	2,765

Baseline characteristics

Characteristic	Adults and Children With ARC
Age, Customized 12 to 17 years of age	173 participants
Age, Customized 18 to 24 years of age	164 participants
Age, Customized 25 to 34 years of age	223 participants
Age, Customized 35 to 44 years of age	364 participants
Age, Customized 45 to 54 years of age	491 participants
Age, Customized 55 to 64 years of age	515 participants
Age, Customized 5 to 11 years of age	205 participants
Age, Customized 65+ years of age	597 participants
Age, Customized Don't Know/Refused	33 participants
Sex/Gender, Customized Female	581 participants
Sex/Gender, Customized Male	333 participants
Sex/Gender, Customized Unknown	1851 participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	0 / 0
serious Total, serious adverse events	0 / 0

Outcome results

Primary

Percentage of Participants Who Experienced Daily Symptoms Due to Allergic Rhinoconjunctivitis (ARC)

Participants were asked about the frequency and severity of ARC symptoms when allergies were at their worst. The percentages of participants who experienced different symptoms of ARC on a daily basis when allergies were at their worst were calculated.